Patents Examined by Kamal Saeed
  • Patent number: 10842777
    Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 24, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Isabella A. Graef, Mamoun M. Alhamadsheh
  • Patent number: 10844027
    Abstract: The present invention provides a compound having the structure of the instant invention of a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instant invention in combination therapies.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 24, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
  • Patent number: 10842795
    Abstract: Compounds for the chemosensitization of antibiotic resistant bacteria such as multidrug resistant (MDR) Pseudomonas aeruginosa (Pa) are provided. The compounds inhibit the MDR efflux proteins and re-sensitize the bacteria towards killing by antibiotics. Thus, the compounds are used in combination with antibiotics to treat or prevent infections caused by MDR bacteria.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 24, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Mahmoud A. Elfaky, Maan T. Khayat, Ghufran A. Alhowswi, Fatma M. Alhaity, Muna M. Albeeshy
  • Patent number: 10836746
    Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: November 17, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas Brizgys, Eda Canales, Chienhung Chou, Michael Graupe, Jiayao Li, Roland D. Saito, Scott D. Schroeder, Winston C. Tse, Qiaoyin Wu, Jennifer R. Zhang
  • Patent number: 10835515
    Abstract: The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 17, 2020
    Assignee: ORION CORPORATION
    Inventors: Olli Törmäkangas, Terhi Heikkinen
  • Patent number: 10829456
    Abstract: The present invention concerns new halogen substituted diketone compounds, new pyrazole compounds, processes for the manufacture of pyrazole compounds and processes for the manufacture of agrochemical or pharmaceutical compounds.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 10, 2020
    Assignee: SOLVAY SA
    Inventors: Suzanne Wassmann, Janis Jaunzems, Stefan Mross, Jean Fabre
  • Patent number: 10829438
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: November 10, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Patent number: 10822315
    Abstract: Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: November 3, 2020
    Assignee: North Carolina State University
    Inventors: Joshua G. Pierce, Grant A. Edwards
  • Patent number: 10822308
    Abstract: The present invention relates to processes for the preparation of eluxadoline and its intermediates.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 3, 2020
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Kdv Jesunadh, Murad Ismail Inamdar, Mukesh Kumar Madhra
  • Patent number: 10826007
    Abstract: A thermally activated delayed fluorescence (TADF) material and an application thereof are provided. The blue TADF material has an electron acceptor which exhibits good structural rigidity so as to improve thermal stability of molecules, and three blue TADF materials with good light-emitting properties are designed and synthesized by selecting different raw material-derived functional groups. Furthermore, the blue TADF material provided by the present invention is used as a luminescent material and is applied to an electroluminescent device that has good luminosity and an excellent effect.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: November 3, 2020
    Assignee: Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd.
    Inventor: Jiajia Luo
  • Patent number: 10815221
    Abstract: The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 27, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Kaiqiang Yan, Qiyue Liu, Xiaoyu Zhang, Jiaoyang Li
  • Patent number: 10808128
    Abstract: The present disclosure relates to chemical dyes useful for staining and imaging of cells. In particular, the disclosure relates to compound of Formula I, method of preparation thereof, and it's use as a fluorescent probe for staining and/or imaging mitochondria in cells, tissues or animals, resulting in a range of applications including, but not limiting, to sensing local ordering or viscosity of mitochondria, tracking mitochondrial mobility, comparing & evaluating mitochondrial function, local ordering, microviscosity and dynamics. Said dyes have additional advantages including, but not limiting, to low toxicity, longer shelf-life, generate little or no reactive species upon long term light irradiation and do not perturb the functionality of the mitochondria in cells compared to prior art dyes.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 20, 2020
    Assignee: INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (INSTEM)
    Inventors: Akash Gulyani, Sufi Oasim Raja, Gandhi Sivaraman
  • Patent number: 10799482
    Abstract: A process for preparing an amorphous form of a compound of formula (I) This amorphous compound I is particularly suitable in treating IPF by pulmonary administration.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: October 13, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Lise Gravelle, Anders Pedersen
  • Patent number: 10793580
    Abstract: The present invention relates to novel pyrazoloazepin-8-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 6, 2020
    Assignee: LEO Pharma A/S
    Inventors: Xifu Liang, Jens Larsen
  • Patent number: 10793552
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 6, 2020
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • Patent number: 10785980
    Abstract: The present invention relates to novel trifluoromethyl oxadiazoles of the formula I, or an N-oxide, and/or their agriculturally useful salts; to their use for controlling phytopathogenic fungi; to a method for combating phytopathogenic harmful fungi, which process comprises treating the fungi or the plants, the soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of the formula I, or an N-oxide, or an agriculturally acceptable salt thereof; to agrochemical compositions comprising at least one such compound; and to agrochemical compositions further comprising seeds.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 29, 2020
    Assignee: BASF SE
    Inventors: Christine Wiebe, Violeta Terteryan-Seiser, Wassilios Grammenos, Ian Robert Craig, Maria Angelica Quintero Palomar, Tobias Mentzel, Marcus Fehr, Christian Harald Winter, Erica Cambeis, Jan Klaas Lohmann, Ana Escribano Cuesta, Manuel Kretschmer, Thomas Grote, Bernd Mueller
  • Patent number: 10786485
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: September 29, 2020
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • Patent number: 10781164
    Abstract: The present invention relates to a process for the N-alkylation of amines by reacting an amine with an orthocarboxylic acid ester and with hydrogen in the presence of a hydrogenation catalyst.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: September 22, 2020
    Assignee: Evonik Operations GmbH
    Inventor: Renat Kadyrov
  • Patent number: 10781212
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: September 22, 2020
    Assignee: Eli Lilly and Company
    Inventor: Timothy Barrett Durham
  • Patent number: 10774054
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu